Survey data suggests that over a third of organizations that relied on US funding for HIV had already closed by February.

Discover why starting HIV treatment promptly preserves immune function, prevents transmission, improves quality of life and ...

Severe mpox and long-term sequelae such as severe scarring were more likely to occur among HIV-positive patients with detectable viral loads and low CD4 counts.

Olga Rivera Ballesteros from the Center for Infectious Medicine (CIM) at the Department of Medicine, Huddinge (MedH) is ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Providing long-acting (LA) antiretroviral therapy (ART) to breastfeeding women with HIV who face adherence challenges may be ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

When it came to innovations in biotech, there was a clear winner: lenacapavir, a drug that was found to prevent HIV infections in 100% of the women and girls who received it in a clinical trial.

Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.

Researchers assessed epidemiologic trends of incident hepatitis C virus infection among patients with HIV infection engaged in care in the US.

Rising infections highlight gaps in prevention efforts as experts urge expanded outreach and awareness campaigns ...